bupivacaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 432 38396-39-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bupivacaine hydrochloride anhydrous
  • bupivacaine
  • (+/-)-Bupivacaine
  • bucain
  • bupivan
  • carbostesin
  • DL-Bupivacaine
  • bupivacaine hydrochloride
  • bupivacaine HCl
A widely used local anesthetic agent.
  • Molecular weight: 288.44
  • Formula: C18H28N2O
  • CLOGP: 3.69
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -3.47
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.18 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.84 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.251 High 0.86
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.374 High 0.86
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 52.966 10^-6 cm/s High 0.86
dh-clint Dog hepatocyte intrinsic clearance 133.968 uL/min/10^6 cells High 0.86
dppb Dog plasma protein binding (% unbound) 17.020 % High 0.86
fcs-ppb Fetal calf serum protein binding (% unbound) 32.070 % High 0.86
herg hERG pIC50 4.851 pIC50 High 0.86
hh-clint Human hepatocyte intrinsic clearance 24.434 uL/min/10^6 cells High 0.86
hlm-clint Human liver microsomal intrinsic clearance 192.752 uL/min/mg protein High 0.86
hppb Human plasma protein binding (% unbound) 11.740 % High 0.86
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK 22
kinase-selectivity-class AXL,BRAF,DDR1,EPHB4,ERBB2,GRK2,MAPK7,PDK4,SIK2,SIK3 10
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.551 High 0.86
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.328 High 0.86
mh-clint Mouse hepatocyte intrinsic clearance 319.890 High 0.86
mppb Mouse plasma protein binding (% unbound) 24.490 High 0.86
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.752 High 0.86
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 33.850 % High 0.86
rat-kpuu-brain Rat brain Kpuu 1.426 % High 0.86
rh-clint Rat hepatocyte intrinsic clearance 286.418 uL/min/10^6 cells High 0.86
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.230 % High 0.86
rppb Rat plasma protein binding (% unbound) 22.110 % High 0.86
solubility-dd Solubility at pH 7.4 in DMSO 501.187 uM High 0.86

Approvals:

DateAgencyCompanyOrphan
Oct. 3, 1972 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 2132.41 13.69 392 22853 2073 90603129
Maternal exposure during delivery 1349.63 13.69 288 22957 3558 90601644
Exposure during pregnancy 594.88 13.69 490 22755 237920 90367282
Maternal exposure during pregnancy 522.88 13.69 547 22698 359516 90245686
Hypotension 489.60 13.69 504 22741 324893 90280309
Local anaesthetic systemic toxicity 458.87 13.69 118 23127 3382 90601820
Drug ineffective 409.33 13.69 1009 22236 1383289 89221913
Chondrolysis 317.73 13.69 55 23190 190 90605012
Bradycardia 250.46 13.69 192 23053 83655 90521547
Cauda equina syndrome 218.41 13.69 54 23191 1313 90603889
Incorrect route of product administration 208.62 13.69 141 23104 50485 90554717
Anterior spinal artery syndrome 206.76 13.69 37 23208 162 90605040
Premature delivery 201.67 13.69 125 23120 38637 90566565
Drug withdrawal syndrome 155.43 13.69 95 23150 28628 90576574
Overlap syndrome 147.48 13.69 62 23183 8486 90596716
Cardiac arrest 147.16 13.69 157 23088 104778 90500424
Paralysis 145.40 13.69 67 23178 11411 90593791
Normal newborn 141.28 13.69 83 23162 23279 90581923
Wrong product administered 136.95 13.69 57 23188 7608 90597594
Labelled drug-drug interaction medication error 133.06 13.69 68 23177 14514 90590688
Respiratory depression 123.19 13.69 66 23179 15509 90589693
Unresponsive to stimuli 119.69 13.69 90 23155 38031 90567171
Implant site extravasation 119.55 13.69 28 23217 537 90604665
Procedural hypotension 112.21 13.69 33 23212 1567 90603635
Diarrhoea 105.40 13.69 55 23190 939135 89666067
Myoclonus 105.24 13.69 64 23181 19104 90586098
Extradural haematoma 103.86 13.69 33 23212 2035 90603167
Rhythm idioventricular 101.66 13.69 23 23222 376 90604826
Spinal cord injury 100.81 13.69 28 23217 1081 90604121
Caesarean section 94.29 13.69 59 23186 18518 90586684
Inadequate analgesia 93.21 13.69 34 23211 3190 90602012
Apnoea 92.02 13.69 46 23199 9368 90595834
Generalised tonic-clonic seizure 89.24 13.69 73 23172 34830 90570372
Post lumbar puncture syndrome 87.78 13.69 24 23221 873 90604329
Lagophthalmos 87.41 13.69 21 23224 451 90604751
Ventilation perfusion mismatch 82.68 13.69 21 23224 571 90604631
Spinal cord infarction 82.10 13.69 19 23226 345 90604857
Hypoaesthesia 81.95 13.69 220 23025 313990 90291212
Delayed recovery from anaesthesia 80.01 13.69 23 23222 1007 90604195
Fatigue 79.87 13.69 108 23137 1153915 89451287
Arachnoiditis 77.98 13.69 20 23225 566 90604636
Seizure 77.77 13.69 140 23105 152489 90452713
Urinary retention 72.37 13.69 67 23178 37677 90567525
Rheumatoid arthritis 70.72 13.69 6 23239 362608 90242594
Anaphylactic shock 70.26 13.69 61 23184 31556 90573646
Hyperaesthesia 69.94 13.69 40 23205 10662 90594540
Paraplegia 69.93 13.69 28 23217 3384 90601818
Loss of consciousness 69.36 13.69 127 23118 140111 90465091
Medical device site pain 67.82 13.69 15 23230 220 90604982
Rash 67.54 13.69 63 23182 796037 89809165
Anaphylactic reaction 67.53 13.69 97 23148 87427 90517775
Live birth 67.47 13.69 92 23153 79015 90526187
Hypothermia 65.59 13.69 44 23201 15531 90589671
Circulatory collapse 65.58 13.69 53 23192 24851 90580351
Premature baby 65.26 13.69 53 23192 25024 90580178
Purtscher retinopathy 62.74 13.69 13 23232 137 90605065
Sedation 62.11 13.69 69 23176 48102 90557100
Hypoxia 61.44 13.69 84 23161 72315 90532887
Procedural complication 61.25 13.69 30 23215 5848 90599354
Foetal exposure during delivery 60.65 13.69 15 23230 365 90604837
Brachial plexopathy 60.50 13.69 14 23231 254 90604948
Pneumonia 59.57 13.69 46 23199 638013 89967189
Therapeutic product effect prolonged 59.37 13.69 15 23230 399 90604803
Joint swelling 55.52 13.69 30 23215 503270 90101932
Post procedural complication 55.45 13.69 43 23202 18999 90586203
Bradycardia foetal 54.41 13.69 15 23230 563 90604639
Parophthalmia 54.15 13.69 14 23231 409 90604793
Conjunctival oedema 50.89 13.69 16 23229 953 90604249
Sensory loss 50.86 13.69 40 23205 18035 90587167
Spinal anaesthesia 50.74 13.69 10 23235 80 90605122
Blood pressure decreased 50.59 13.69 78 23167 74817 90530385
No adverse event 50.47 13.69 74 23171 67908 90537294
Hypertensive encephalopathy 50.45 13.69 15 23230 740 90604462
Haemodynamic instability 49.04 13.69 33 23212 11706 90593496
Meningitis chemical 48.96 13.69 12 23233 281 90604921
Systemic lupus erythematosus 48.82 13.69 16 23229 361880 90243322
Platelet aggregation inhibition 48.72 13.69 11 23234 178 90605024
Diplegia 48.07 13.69 17 23228 1458 90603744
Horner's syndrome 47.07 13.69 8 23237 24 90605178
Uterine atony 46.91 13.69 12 23233 336 90604866
Neurotoxicity 46.85 13.69 41 23204 21426 90583776
Postpartum haemorrhage 46.78 13.69 19 23226 2382 90602820
Neuromuscular blockade 46.31 13.69 12 23233 354 90604848
Vascular resistance systemic decreased 46.12 13.69 10 23235 133 90605069
Arachnoid web 46.03 13.69 7 23238 7 90605195
Therapeutic product effect delayed 45.31 13.69 21 23224 3620 90601582
Peripheral swelling 44.99 13.69 25 23220 413081 90192121
Pemphigus 44.88 13.69 14 23231 326850 90278352
Overdose 44.69 13.69 114 23131 157595 90447607
Motor dysfunction 44.54 13.69 38 23207 19192 90586010
Pulseless electrical activity 44.40 13.69 28 23217 8904 90596298
Mental status changes postoperative 42.88 13.69 10 23235 188 90605014
Intracranial hypotension 42.08 13.69 11 23234 336 90604866
Exophthalmos 41.18 13.69 16 23229 1786 90603416
Neuralgia 40.39 13.69 45 23200 31455 90573747
Procedural pain 39.96 13.69 46 23199 33314 90571888
Stridor 39.84 13.69 21 23224 4772 90600430
Cough 39.21 13.69 23 23222 368939 90236263
Product dose omission issue 39.15 13.69 13 23232 291674 90313528
Monoplegia 39.02 13.69 19 23226 3655 90601547
Ventricular tachycardia 38.23 13.69 39 23206 24669 90580533
Neutropenia 38.16 13.69 6 23239 224898 90380304
Spinal cord oedema 37.74 13.69 9 23236 187 90605015
Arthropathy 37.29 13.69 24 23221 366218 90238984
Respiratory arrest 36.69 13.69 44 23201 33267 90571935
Myelitis 35.60 13.69 15 23230 2063 90603139
Accidental overdose 35.58 13.69 40 23205 28233 90576969
Acute kidney injury 35.44 13.69 19 23226 320368 90284834
Device infusion issue 35.16 13.69 16 23229 2646 90602556
Depressed level of consciousness 34.81 13.69 65 23180 72719 90532483
Synovitis 34.41 13.69 21 23224 329731 90275471
Spinal cord compression 33.83 13.69 19 23226 4892 90600310
Tachycardia 33.82 13.69 103 23142 157570 90447632
Mental status changes 33.69 13.69 49 23196 44630 90560572
Trigeminal palsy 33.68 13.69 7 23238 75 90605127
Low birth weight baby 33.42 13.69 24 23221 9443 90595759
Strabismus 33.12 13.69 15 23230 2453 90602749
Myelitis transverse 32.98 13.69 13 23232 1507 90603695
Complication associated with device 32.48 13.69 32 23213 19417 90585785
Fall 32.25 13.69 46 23199 481764 90123438
Necrotising fasciitis 32.25 13.69 17 23228 3863 90601339
Wound 32.02 13.69 19 23226 302961 90302241
Therapy non-responder 31.88 13.69 92 23153 136612 90468590
Respiratory rate decreased 31.83 13.69 17 23228 3966 90601236
Peripartum cardiomyopathy 31.76 13.69 8 23237 210 90604992
Ophthalmoplegia 31.22 13.69 13 23232 1736 90603466
Neuromuscular block prolonged 31.08 13.69 10 23235 642 90604560
Bezold-Jarisch reflex 30.90 13.69 6 23239 44 90605158
Sensory disturbance 30.78 13.69 28 23217 15385 90589817
Confusion postoperative 30.65 13.69 8 23237 243 90604959
Areflexia 30.35 13.69 16 23229 3637 90601565
Anaemia 29.73 13.69 28 23217 352774 90252428
Sensorimotor disorder 29.64 13.69 10 23235 745 90604457
Pyrexia 29.56 13.69 80 23165 660405 89944797
Muscular weakness 29.53 13.69 118 23127 206548 90398654
Cerebrospinal fluid leakage 29.16 13.69 12 23233 1555 90603647
Uterine hypertonus 28.70 13.69 8 23237 313 90604889
Pericarditis 28.46 13.69 17 23228 270134 90335068
Medical device site erythema 28.30 13.69 5 23240 20 90605182
Arteriospasm coronary 28.07 13.69 17 23228 5033 90600169
Urinary tract infection 27.25 13.69 23 23222 305609 90299593
Allodynia 26.66 13.69 10 23235 1014 90604188
Product formulation issue 26.63 13.69 9 23236 674 90604528
Kounis syndrome 26.51 13.69 13 23232 2540 90602662
Harlequin syndrome 26.40 13.69 7 23238 226 90604976
Contraindicated product administered 26.28 13.69 26 23219 320113 90285089
Nasopharyngitis 26.13 13.69 40 23205 407064 90198138
Lower respiratory tract infection 26.09 13.69 16 23229 250643 90354559
Bundle branch block left 25.59 13.69 19 23226 7866 90597336
Device failure 25.53 13.69 18 23227 6879 90598323
Product measured potency issue 25.52 13.69 6 23239 117 90605085
Death 25.51 13.69 49 23196 456502 90148700
Arthralgia 25.49 13.69 108 23137 778414 89826788
Influenza 25.31 13.69 3 23242 139261 90465941
Systemic toxicity 25.23 13.69 7 23238 269 90604933
Eclampsia 25.23 13.69 8 23237 490 90604712
Maternal drugs affecting foetus 25.22 13.69 16 23229 5139 90600063
Implant site infection 25.21 13.69 10 23235 1179 90604023
Febrile neutropenia 25.17 13.69 5 23240 158344 90446858
Product closure issue 25.03 13.69 4 23241 7 90605195
Adverse drug reaction 24.80 13.69 76 23169 116625 90488577
Anaesthetic complication cardiac 24.74 13.69 5 23240 46 90605156
Nerve block 24.55 13.69 9 23236 856 90604346
Gastrointestinal disorder 24.54 13.69 18 23227 256669 90348533
Product administration error 24.46 13.69 32 23213 26391 90578811
Vocal cord paralysis 24.12 13.69 12 23233 2418 90602784
Chondromalacia 23.95 13.69 7 23238 325 90604877
Hypercapnia 23.74 13.69 17 23228 6660 90598542
Weight decreased 23.74 13.69 38 23207 379872 90225330
Myopathy toxic 23.58 13.69 8 23237 606 90604596
Fanconi syndrome 23.54 13.69 11 23234 1932 90603270
Implant site pain 23.30 13.69 12 23233 2600 90602602
Malaise 23.29 13.69 75 23170 585911 90019291
White blood cell count decreased 23.21 13.69 7 23238 167102 90438100
Nervous system disorder 22.92 13.69 28 23217 21565 90583637
Respiratory acidosis 22.91 13.69 18 23227 8101 90597101
Off label use 22.89 13.69 403 22842 1101849 89503353
Obstetric procedure complication 22.45 13.69 4 23241 17 90605185
Maternal use of illicit drugs 22.26 13.69 4 23241 18 90605184
Glossodynia 22.23 13.69 30 23215 321749 90283453
Mean arterial pressure decreased 22.11 13.69 6 23239 212 90604990
Alopecia 22.10 13.69 60 23185 495011 90110191
Office visit 21.81 13.69 3 23242 0 90605202
Conus medullaris syndrome 21.81 13.69 3 23242 0 90605202
Respiratory distress 21.45 13.69 37 23208 38909 90566293
Arthrofibrosis 21.44 13.69 4 23241 23 90605179
Uterine haemorrhage 21.40 13.69 14 23231 4738 90600464
Hypoaesthesia oral 21.23 13.69 23 23222 15577 90589625
Hand deformity 21.12 13.69 27 23218 296335 90308867
Product quality issue 21.07 13.69 56 23189 79269 90525933
Cancer pain 20.97 13.69 13 23232 4012 90601190
Drug intolerance 20.92 13.69 53 23192 447538 90157664
Device alarm issue 20.78 13.69 10 23235 1875 90603327
Duodenal ulcer perforation 20.53 13.69 16 23229 221272 90383930
Incision site pain 20.49 13.69 9 23236 1369 90603833
Device malfunction 20.35 13.69 26 23219 20951 90584251
Completed suicide 20.28 13.69 6 23239 145052 90460150
COVID-19 20.19 13.69 9 23236 168834 90436368
Subdural haematoma 20.01 13.69 23 23222 16622 90588580
Blood pressure immeasurable 19.80 13.69 9 23236 1483 90603719
Pneumorrhachis 19.73 13.69 3 23242 3 90605199
Anti-cyclic citrullinated peptide antibody positive 19.63 13.69 19 23226 236414 90368788
Infusion site mass 19.36 13.69 10 23235 2179 90603023
Dose calculation error 19.29 13.69 6 23239 345 90604857
Disease progression 19.28 13.69 8 23237 156607 90448595
Abdominal discomfort 19.01 13.69 61 23184 477267 90127935
Peroneal nerve palsy 18.99 13.69 14 23231 5734 90599468
Withdrawal syndrome 18.90 13.69 26 23219 22498 90582704
Blood pressure systolic decreased 18.82 13.69 17 23228 9253 90595949
Agitation 18.47 13.69 48 23197 67050 90538152
Prescribed overdose 18.38 13.69 61 23184 97564 90507638
Pulse absent 18.34 13.69 14 23231 6041 90599161
Bradyarrhythmia 18.26 13.69 10 23235 2451 90602751
Manipulation 18.13 13.69 4 23241 58 90605144
Atrioventricular block complete 18.00 13.69 17 23228 9794 90595408
Quadriparesis 17.93 13.69 10 23235 2539 90602663
Ventricular fibrillation 17.89 13.69 20 23225 14024 90591178
Sphincter of Oddi dysfunction 17.74 13.69 6 23239 450 90604752
Weight increased 17.64 13.69 52 23193 417875 90187327
Ventricular hypokinesia 17.63 13.69 13 23232 5328 90599874
Spinal epidural haematoma 17.56 13.69 8 23237 1326 90603876
Rotator cuff syndrome 17.48 13.69 21 23224 15898 90589304
Psoriasis 17.47 13.69 8 23237 147746 90457456
Abdominal pain upper 17.46 13.69 37 23208 332637 90272565
Paresis 17.35 13.69 10 23235 2704 90602498
Intraocular pressure fluctuation 17.26 13.69 4 23241 73 90605129
Spinal cord haematoma 17.24 13.69 5 23240 226 90604976
Product packaging confusion 17.19 13.69 5 23240 228 90604974
Extra dose administered 17.11 13.69 16 23229 9102 90596100
Myalgia 17.10 13.69 12 23233 175113 90430089
Implant site haematoma 16.82 13.69 4 23241 82 90605120
Neurogenic shock 16.80 13.69 6 23239 530 90604672
Cardiac output increased 16.78 13.69 6 23239 531 90604671
Infusion related reaction 16.78 13.69 53 23192 416727 90188475
Pulmonary oedema 16.66 13.69 44 23201 62036 90543166
Wheezing 16.64 13.69 22 23223 238058 90367144
Wound dehiscence 16.63 13.69 13 23232 5809 90599393
Somnolence 16.62 13.69 101 23144 208983 90396219
Blood creatinine increased 16.54 13.69 3 23242 101383 90503819
Vasospasm 16.48 13.69 7 23238 982 90604220
Therapeutic product effect variable 16.47 13.69 8 23237 1531 90603671
Brain hypoxia 16.45 13.69 6 23239 563 90604639
Device kink 16.43 13.69 9 23236 2206 90602996
Hypovolaemia 16.35 13.69 18 23227 12413 90592789
Pre-eclampsia 16.30 13.69 17 23228 11031 90594171
Seroma 16.24 13.69 10 23235 3050 90602152
Retinal artery occlusion 16.22 13.69 9 23236 2262 90602940
Status epilepticus 16.15 13.69 22 23223 18852 90586350
Stroke volume increased 15.97 13.69 3 23242 18 90605184
Cardiac failure congestive 15.93 13.69 3 23242 98691 90506511
Hyponatraemic encephalopathy 15.85 13.69 5 23240 301 90604901
Arthritis bacterial 15.80 13.69 14 23231 7431 90597771
Contusion 15.80 13.69 25 23220 251191 90354011
Neurological procedural complication 15.70 13.69 3 23242 20 90605182
Foetal distress syndrome 15.69 13.69 8 23237 1697 90603505
Hypoglycaemia neonatal 15.63 13.69 7 23238 1115 90604087
Post procedural hypotension 15.45 13.69 3 23242 22 90605180
Renal impairment 15.41 13.69 4 23241 105417 90499785
Brain injury 15.34 13.69 14 23231 7724 90597478
Infection 15.32 13.69 45 23200 362049 90243153
Tinnitus 15.26 13.69 34 23211 43068 90562134
Sleep disorder 15.21 13.69 17 23228 198013 90407189
Phrenic nerve paralysis 15.19 13.69 5 23240 345 90604857
Anaesthetic complication neurological 14.90 13.69 6 23239 735 90604467
Thrombocytopenia 14.88 13.69 19 23226 208706 90396496
Therapeutic product effect increased 14.65 13.69 7 23238 1292 90603910
Product package associated injury 14.62 13.69 3 23242 30 90605172
Decreased ventricular preload 14.62 13.69 3 23242 30 90605172
Dehydration 14.60 13.69 17 23228 194430 90410772
Acute pulmonary oedema 14.60 13.69 15 23230 9565 90595637
Leukopenia 14.38 13.69 4 23241 100706 90504496
Sinus tachycardia 14.30 13.69 26 23219 28487 90576715
Cardio-respiratory arrest 14.24 13.69 42 23203 63098 90542104
Gastrooesophageal reflux disease 14.23 13.69 13 23232 166324 90438878
Left ventricle outflow tract obstruction 14.16 13.69 5 23240 427 90604775
Renal failure 14.14 13.69 8 23237 130999 90474203
Catatonia 14.09 13.69 12 23233 6044 90599158
Gastrointestinal haemorrhage 14.03 13.69 3 23242 90245 90514957
Rheumatoid factor positive 14.01 13.69 14 23231 171636 90433566
Oropharyngeal pain 13.99 13.69 6 23239 115181 90490021
Iatrogenic injury 13.99 13.69 6 23239 862 90604340
Incision site rash 13.90 13.69 3 23242 39 90605163
Granuloma 13.87 13.69 12 23233 6173 90599029
Liver injury 13.82 13.69 14 23231 170553 90434649
Ventricular extrasystoles 13.77 13.69 17 23228 13233 90591969
Loss of personal independence in daily activities 13.72 13.69 9 23236 136096 90469106
Brugada syndrome 13.70 13.69 5 23240 470 90604732

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 767.47 21.48 150 9627 1307 42610251
Local anaesthetic systemic toxicity 258.31 21.48 67 9710 2233 42609325
Chondrolysis 257.99 21.48 41 9736 81 42611477
Drug withdrawal syndrome 142.40 21.48 78 9699 21471 42590087
Drug ineffective 124.94 21.48 370 9407 629827 41981731
Pain 124.34 21.48 210 9567 244638 42366920
Hyperaesthesia 113.75 21.48 45 9732 5907 42605651
Hypoaesthesia 106.79 21.48 105 9672 71358 42540200
Cauda equina syndrome 88.35 21.48 24 9753 956 42610602
Inspiratory capacity decreased 88.11 21.48 31 9746 2936 42608622
Myoclonus 81.39 21.48 50 9727 17015 42594543
Paralysis 80.65 21.48 37 9740 6983 42604575
Retinal artery occlusion 76.86 21.48 26 9751 2189 42609369
Respiratory depression 74.34 21.48 49 9728 18819 42592739
Incorrect route of product administration 72.04 21.48 53 9724 24252 42587306
Bradycardia 71.65 21.48 93 9684 85391 42526167
Cardiac arrest 67.91 21.48 103 9674 109217 42502341
Lagophthalmos 64.99 21.48 13 9764 128 42611430
Anal incontinence 64.82 21.48 35 9742 9346 42602212
Sinus arrest 62.01 21.48 22 9755 2134 42609424
Paraplegia 59.76 21.48 24 9753 3273 42608285
Hypotension 55.01 21.48 156 9621 257475 42354083
Cardiotoxicity 54.88 21.48 29 9748 7416 42604142
Spinal cord infarction 53.97 21.48 15 9762 651 42610907
Medical device site pain 51.97 21.48 10 9767 79 42611479
Device failure 49.83 21.48 20 9757 2723 42608835
Sensory loss 49.16 21.48 24 9753 5200 42606358
Kounis syndrome 49.15 21.48 21 9756 3347 42608211
Urinary incontinence 48.45 21.48 40 9737 21628 42589930
Apnoea 48.09 21.48 27 9750 7776 42603782
Post procedural hypotension 46.89 21.48 9 9768 70 42611488
Therapeutic product effect delayed 45.53 21.48 16 9761 1509 42610049
Neurotoxicity 45.40 21.48 40 9737 23611 42587947
Muscular weakness 45.32 21.48 74 9703 83424 42528134
Corneal reflex decreased 44.78 21.48 10 9767 173 42611385
Premature baby 44.13 21.48 39 9738 23114 42588444
Device malfunction 43.72 21.48 30 9747 12297 42599261
Generalised tonic-clonic seizure 43.56 21.48 41 9736 26338 42585220
Loss of consciousness 42.42 21.48 76 9701 92278 42519280
Arachnoiditis 41.91 21.48 11 9766 383 42611175
Delayed recovery from anaesthesia 41.65 21.48 14 9763 1155 42610403
Autonomic nervous system imbalance 40.80 21.48 18 9759 3098 42608460
Implant site pain 40.73 21.48 9 9768 148 42611410
Implant site extravasation 40.16 21.48 11 9766 452 42611106
Anaphylactic reaction 39.72 21.48 49 9728 42694 42568864
Pneumonia 39.63 21.48 24 9753 422125 42189433
Device infusion issue 38.41 21.48 13 9764 1095 42610463
Procedural pain 38.36 21.48 21 9756 5758 42605800
Sodium retention 38.25 21.48 8 9769 100 42611458
Spinal shock 37.91 21.48 7 9770 43 42611515
Areflexia 37.64 21.48 18 9759 3725 42607833
Oculocardiac reflex 37.08 21.48 8 9769 117 42611441
Therapy non-responder 37.00 21.48 53 9724 53306 42558252
Wrong product administered 36.90 21.48 21 9756 6205 42605353
Arthrofibrosis 35.97 21.48 7 9770 59 42611499
Sedation 35.08 21.48 39 9738 30436 42581122
Low birth weight baby 34.76 21.48 24 9753 9931 42601627
Anal sphincter atony 34.73 21.48 8 9769 160 42611398
Acute kidney injury 34.29 21.48 21 9756 367316 42244242
Amaurosis 33.57 21.48 11 9766 838 42610720
Renin increased 32.95 21.48 8 9769 202 42611356
Procedural complication 32.70 21.48 17 9760 4202 42607356
Anaemia 32.29 21.48 12 9765 280266 42331292
Post procedural complication 31.87 21.48 25 9752 12565 42598993
Labelled drug-drug interaction medication error 31.20 21.48 27 9750 15555 42596003
Myopathy toxic 30.92 21.48 10 9767 731 42610827
Unresponsive to stimuli 30.79 21.48 37 9740 31366 42580192
Paraparesis 30.50 21.48 13 9764 2058 42609500
Complication associated with device 30.38 21.48 19 9758 6662 42604896
Thrombocytopenia 30.17 21.48 4 9773 190275 42421283
Overdose 29.84 21.48 71 9706 105193 42506365
Paroxysmal sympathetic hyperactivity 29.73 21.48 6 9771 62 42611496
Symmetrical drug-related intertriginous and flexural exanthema 29.37 21.48 10 9767 858 42610700
Diaphragmatic paralysis 29.08 21.48 9 9768 570 42610988
Macular ischaemia 28.60 21.48 7 9770 183 42611375
Device power source issue 28.56 21.48 9 9768 605 42610953
Deafness bilateral 28.22 21.48 11 9766 1386 42610172
Diarrhoea 28.05 21.48 39 9738 460810 42150748
Infusion site mass 27.96 21.48 8 9769 386 42611172
Product administration error 27.43 21.48 27 9750 18316 42593242
Axillary pain 27.23 21.48 8 9769 424 42611134
Electrocardiogram T wave amplitude increased 27.02 21.48 6 9771 101 42611457
Anaesthetic complication neurological 26.96 21.48 9 9768 727 42610831
Death 26.61 21.48 42 9735 471143 42140415
Jaundice cholestatic 26.59 21.48 16 9761 5237 42606321
Sinus tachycardia 26.51 21.48 28 9749 20625 42590933
Muscle rigidity 26.40 21.48 22 9755 12037 42599521
Brief psychotic disorder with marked stressors 26.06 21.48 7 9770 267 42611291
No adverse event 25.94 21.48 38 9739 38983 42572575
Coma 25.76 21.48 45 9732 53509 42558049
Foetal exposure during delivery 25.59 21.48 6 9771 130 42611428
Mental status changes 25.13 21.48 39 9738 42076 42569482
Inadequate analgesia 25.12 21.48 13 9764 3184 42608374
Apgar score low 24.57 21.48 9 9768 956 42610602
Implant site erythema 24.49 21.48 5 9772 55 42611503
Brown-Sequard syndrome 24.41 21.48 5 9772 56 42611502
Foetal exposure during pregnancy 24.40 21.48 41 9736 47270 42564288
Tachycardia 24.25 21.48 64 9713 101023 42510535
Blood pressure decreased 24.24 21.48 46 9731 58286 42553272
Femoral nerve palsy 24.02 21.48 5 9772 61 42611497
Ventricular tachycardia 23.96 21.48 32 9745 30128 42581430
Hypercapnia 23.76 21.48 15 9762 5346 42606212
Phrenic nerve paralysis 23.47 21.48 6 9771 188 42611370
Hyperhidrosis 23.46 21.48 59 9718 90453 42521105
Ophthalmoplegia 23.41 21.48 11 9766 2189 42609369
Open globe injury 22.87 21.48 5 9772 78 42611480
Strabismus 22.73 21.48 11 9766 2337 42609221
Meningitis chemical 22.25 21.48 5 9772 89 42611469
Somnolence 22.20 21.48 77 9700 141028 42470530
Pre-existing disease 22.15 21.48 5 9772 91 42611467
Bezold-Jarisch reflex 22.14 21.48 3 9774 0 42611558
Catheter site mass 21.89 21.48 4 9773 23 42611535
Chondromalacia 21.89 21.48 4 9773 23 42611535
Hypothermia 21.71 21.48 20 9757 12495 42599063

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 2310.64 13.69 446 28132 3160 110557561
Maternal exposure during delivery 1147.27 13.69 249 28329 3316 110557405
Maternal exposure during pregnancy 601.15 13.69 509 28069 254374 110306347
Chondrolysis 552.22 13.69 94 28484 283 110560438
Local anaesthetic systemic toxicity 466.97 13.69 132 28446 5405 110555316
Exposure during pregnancy 333.16 13.69 304 28274 167120 110393601
Drug ineffective 311.00 13.69 976 27602 1519564 109041157
Hypotension 300.30 13.69 507 28071 523342 110037379
Cauda equina syndrome 284.70 13.69 73 28505 2049 110558672
Drug withdrawal syndrome 268.90 13.69 150 28428 37904 110522817
Bradycardia 255.31 13.69 254 28324 155263 110405458
Incorrect route of product administration 247.60 13.69 172 28406 63889 110496832
Anterior spinal artery syndrome 215.44 13.69 39 28539 183 110560538
Paralysis 212.53 13.69 96 28482 15504 110545217
Premature delivery 208.94 13.69 118 28460 30514 110530207
Cardiac arrest 190.19 13.69 244 28334 196509 110364212
Myoclonus 182.57 13.69 111 28467 32887 110527834
Hyperaesthesia 176.75 13.69 83 28495 14644 110546077
Respiratory depression 167.74 13.69 104 28474 31897 110528824
Lagophthalmos 150.36 13.69 34 28544 550 110560171
Overlap syndrome 146.84 13.69 63 28515 8996 110551725
Normal newborn 145.68 13.69 83 28495 21813 110538908
Implant site extravasation 139.68 13.69 35 28543 893 110559828
Hypoaesthesia 136.23 13.69 270 28308 313953 110246768
Apnoea 128.04 13.69 65 28513 13574 110547147
Wrong product administered 120.01 13.69 58 28520 10902 110549819
Spinal cord infarction 119.52 13.69 32 28546 1066 110559655
Spinal cord injury 119.41 13.69 35 28543 1630 110559091
Unresponsive to stimuli 117.33 13.69 111 28467 63679 110497042
Extradural haematoma 114.00 13.69 40 28538 3329 110557392
Diarrhoea 113.67 13.69 78 28500 1139427 109421294
Arachnoiditis 111.63 13.69 30 28548 1014 110559707
Paraplegia 110.07 13.69 46 28532 6154 110554567
Delayed recovery from anaesthesia 109.56 13.69 35 28543 2180 110558541
Anaphylactic reaction 109.16 13.69 141 28437 114159 110446562
Loss of consciousness 106.71 13.69 186 28392 196120 110364601
Generalised tonic-clonic seizure 106.05 13.69 98 28480 54582 110506139
Inadequate analgesia 104.92 13.69 42 28536 5035 110555686
Medical device site pain 101.72 13.69 23 28555 372 110560349
Pneumonia 95.64 13.69 54 28524 876660 109684061
Post lumbar puncture syndrome 91.78 13.69 26 28552 1071 110559650
Sedation 91.29 13.69 101 28477 69582 110491139
Labelled drug-drug interaction medication error 88.90 13.69 68 28510 29234 110531487
Retinal artery occlusion 87.28 13.69 35 28543 4214 110556507
Sensory loss 86.11 13.69 59 28519 21398 110539323
Rhythm idioventricular 86.02 13.69 23 28555 762 110559959
Fatigue 80.35 13.69 119 28459 1215839 109344882
Acute kidney injury 78.56 13.69 33 28545 635397 109925324
Ventilation perfusion mismatch 76.33 13.69 21 28557 776 110559945
Kounis syndrome 72.96 13.69 34 28544 5891 110554830
Procedural complication 72.95 13.69 38 28540 8367 110552354
Device failure 72.50 13.69 36 28542 7171 110553550
Neutropenia 71.56 13.69 7 28571 374613 110186108
Hypothermia 71.06 13.69 57 28521 26245 110534476
Seizure 70.50 13.69 168 28410 221017 110339704
Post procedural complication 70.38 13.69 57 28521 26601 110534120
Anaphylactic shock 69.74 13.69 76 28502 51470 110509251
Caesarean section 67.60 13.69 43 28535 13774 110546947
Neurotoxicity 67.41 13.69 68 28510 42139 110518582
Meningitis chemical 66.02 13.69 16 28562 354 110560367
Device infusion issue 65.74 13.69 26 28552 3019 110557702
Brachial plexopathy 63.76 13.69 15 28563 291 110560430
Febrile neutropenia 62.98 13.69 5 28573 316762 110243959
Muscular weakness 62.89 13.69 173 28405 248295 110312426
No adverse event 62.65 13.69 86 28492 73753 110486968
Diplegia 61.87 13.69 23 28555 2258 110558463
Post procedural hypotension 60.91 13.69 12 28566 95 110560626
Anal incontinence 60.19 13.69 48 28530 21916 110538805
Therapeutic product effect prolonged 59.99 13.69 17 28561 701 110560020
Areflexia 59.88 13.69 31 28547 6738 110553983
Anaemia 59.13 13.69 34 28544 547052 110013669
Spinal anaesthesia 59.05 13.69 12 28566 113 110560608
Horner's syndrome 58.51 13.69 10 28568 31 110560690
Rash 58.46 13.69 76 28502 820888 109739833
Bradycardia foetal 58.04 13.69 12 28566 124 110560597
Purtscher retinopathy 56.83 13.69 13 28565 222 110560499
Procedural pain 56.25 13.69 57 28521 35508 110525213
Rheumatoid arthritis 56.17 13.69 6 28572 299607 110261114
Live birth 56.06 13.69 79 28499 69405 110491316
Neuromuscular blockade 54.94 13.69 16 28562 728 110559993
Ventricular tachycardia 54.60 13.69 66 28512 49943 110510778
Sinus arrest 54.28 13.69 25 28553 4217 110556504
Arthrofibrosis 54.28 13.69 11 28567 102 110560619
Monoplegia 53.81 13.69 26 28552 4883 110555838
Myopathy toxic 53.67 13.69 18 28560 1307 110559414
Complication associated with device 53.16 13.69 43 28535 20030 110540691
Spinal cord oedema 52.35 13.69 14 28564 464 110560257
Circulatory collapse 52.34 13.69 60 28518 42933 110517788
Cough 52.33 13.69 27 28551 461614 110099107
Blood pressure decreased 52.31 13.69 101 28477 114990 110445731
Haemodynamic instability 52.26 13.69 45 28533 22843 110537878
Mental status changes 51.97 13.69 80 28498 76042 110484679
Overdose 51.61 13.69 155 28423 233639 110327082
Hypoxia 50.92 13.69 107 28471 129408 110431313
Urinary retention 50.07 13.69 75 28503 69608 110491113
Vascular resistance systemic decreased 50.02 13.69 12 28566 254 110560467
Uterine atony 49.75 13.69 12 28566 260 110560461
Depressed level of consciousness 49.17 13.69 97 28481 112181 110448540
Strabismus 49.13 13.69 22 28556 3477 110557244
Bezold-Jarisch reflex 48.14 13.69 9 28569 52 110560669
Urinary incontinence 48.02 13.69 61 28517 48526 110512195
Platelet aggregation inhibition 47.49 13.69 11 28567 199 110560522
Parophthalmia 46.18 13.69 13 28565 523 110560198
Arachnoid web 45.98 13.69 7 28571 7 110560714
Spinal cord compression 45.90 13.69 27 28551 7525 110553196
Anaesthetic complication neurological 45.70 13.69 15 28563 1018 110559703
Ophthalmoplegia 45.67 13.69 21 28557 3529 110557192
Hypercapnia 45.52 13.69 31 28547 11128 110549593
Pulseless electrical activity 44.59 13.69 36 28542 16721 110544000
Product dose omission issue 44.30 13.69 14 28564 321768 110238953
Chondromalacia 44.09 13.69 10 28568 164 110560557
Motor dysfunction 43.96 13.69 42 28536 24364 110536357
Therapeutic product effect delayed 43.95 13.69 22 28556 4457 110556264
Postpartum haemorrhage 43.85 13.69 17 28561 1872 110558849
Product administration error 43.73 13.69 51 28527 37166 110523555
Death 43.52 13.69 71 28507 698798 109861923
Hypertensive encephalopathy 43.36 13.69 15 28563 1196 110559525
Sensory disturbance 43.35 13.69 36 28542 17393 110543328
Spinal shock 43.28 13.69 8 28570 43 110560678
Tachycardia 42.45 13.69 142 28436 226503 110334218
Allodynia 42.24 13.69 17 28561 2066 110558655
Implant site pain 41.23 13.69 17 28561 2198 110558523
Respiratory arrest 40.82 13.69 62 28516 58237 110502484
Exophthalmos 40.80 13.69 17 28561 2256 110558465
Device malfunction 40.48 13.69 41 28537 25517 110535204
Completed suicide 40.35 13.69 7 28571 242374 110318347
Myelitis transverse 39.90 13.69 17 28561 2384 110558337
Conjunctival oedema 39.69 13.69 15 28563 1541 110559180
Pyrexia 39.49 13.69 111 28467 898154 109662567
Neuromuscular block prolonged 39.13 13.69 14 28564 1233 110559488
Autonomic nervous system imbalance 38.68 13.69 22 28556 5758 110554963
Inspiratory capacity decreased 38.63 13.69 17 28561 2578 110558143
Cancer pain 38.00 13.69 23 28555 6749 110553972
Sinus tachycardia 38 13.69 52 28526 44441 110516280
Thrombocytopenia 37.21 13.69 22 28556 348863 110211858
Mental status changes postoperative 37.10 13.69 9 28569 200 110560521
Peripheral swelling 37.09 13.69 30 28548 404004 110156717
Systemic toxicity 36.81 13.69 10 28568 352 110560369
Paresis 36.68 13.69 20 28558 4824 110555897
Therapy non-responder 36.32 13.69 106 28472 157201 110403520
Phrenic nerve paralysis 36.28 13.69 11 28567 576 110560145
Sensorimotor disorder 36.18 13.69 13 28565 1159 110559562
Macular ischaemia 35.82 13.69 9 28569 232 110560489
Oculocardiac reflex 35.76 13.69 8 28570 123 110560598
White blood cell count decreased 35.30 13.69 8 28570 229382 110331339
Myelitis 35.16 13.69 17 28561 3196 110557525
Paraparesis 34.99 13.69 19 28559 4547 110556174
Neuralgia 34.57 13.69 52 28526 48426 110512295
Conus medullaris syndrome 34.06 13.69 7 28571 70 110560651
Trigeminal palsy 33.62 13.69 7 28571 75 110560646
COVID-19 33.12 13.69 11 28567 245049 110315672
Corneal reflex decreased 32.63 13.69 10 28568 543 110560178
Stridor 32.59 13.69 21 28557 6874 110553847
Peripartum cardiomyopathy 32.55 13.69 8 28570 188 110560533
Joint swelling 32.49 13.69 40 28538 442805 110117916
Diaphragmatic paralysis 31.30 13.69 12 28566 1282 110559439
Adverse drug reaction 31.27 13.69 78 28500 105481 110455240
Intracranial hypotension 31.22 13.69 10 28568 628 110560093
Disease progression 31.20 13.69 12 28566 244022 110316699
Malaise 31.01 13.69 81 28497 671738 109888983
Cardiotoxicity 30.31 13.69 29 28549 16852 110543869
Influenza 30.16 13.69 4 28574 169097 110391624
Blood pressure immeasurable 30.13 13.69 14 28564 2409 110558312
Systemic lupus erythematosus 30.12 13.69 14 28564 254324 110306397
Arteriospasm coronary 29.55 13.69 22 28556 9078 110551643
Uterine hypertonus 29.44 13.69 8 28570 282 110560439
Gastrointestinal haemorrhage 29.32 13.69 4 28574 165514 110395207
Somnolence 29.29 13.69 153 28425 297296 110263425
Nerve block 29.13 13.69 10 28568 779 110559942
Necrotising fasciitis 28.41 13.69 20 28558 7571 110553150
Arthritis bacterial 28.27 13.69 23 28555 10797 110549924
Renal impairment 28.15 13.69 7 28571 188438 110372283
Arthropathy 28.10 13.69 20 28558 287502 110273219
Brown-Sequard syndrome 28.05 13.69 6 28572 74 110560647
Infusion site mass 27.94 13.69 12 28566 1716 110559005
Medical device site erythema 27.83 13.69 6 28572 77 110560644
Manipulation 27.75 13.69 6 28572 78 110560643
Confusion postoperative 27.56 13.69 8 28570 360 110560361
Eclampsia 27.47 13.69 8 28570 364 110560357
Pulse absent 27.41 13.69 23 28555 11269 110549452
Hyponatraemia 27.33 13.69 11 28567 217642 110343079
Pain 27.31 13.69 371 28207 954584 109606137
Respiratory acidosis 27.22 13.69 25 28553 13801 110546920
Respiratory rate decreased 27.00 13.69 18 28560 6240 110554481
Blood creatinine increased 26.92 13.69 7 28571 182882 110377839
Rotator cuff syndrome 26.71 13.69 27 28551 16767 110543954
Dehydration 26.60 13.69 20 28558 279491 110281230
Catheter site granuloma 26.59 13.69 6 28572 96 110560625
Open globe injury 26.41 13.69 7 28571 224 110560497
Infusion related reaction 26.33 13.69 36 28542 381126 110179595
Therapeutic response prolonged 26.27 13.69 4 28574 4 110560717
Ventricular fibrillation 26.22 13.69 42 28536 41271 110519450
Respiratory distress 26.01 13.69 56 28522 68818 110491903
Weight decreased 26.00 13.69 51 28527 468006 110092715
Diplopia 25.78 13.69 42 28536 41852 110518869
Arthralgia 25.66 13.69 109 28469 779523 109781198
Amaurosis 25.58 13.69 11 28567 1578 110559143
Accidental overdose 25.41 13.69 47 28531 51787 110508934
Harlequin syndrome 25.30 13.69 7 28571 264 110560457
Uterine haemorrhage 25.28 13.69 14 28564 3480 110557241
Pemphigus 25.12 13.69 12 28566 214558 110346163
Anal sphincter atony 24.90 13.69 8 28570 507 110560214
Nasopharyngitis 24.57 13.69 40 28538 394321 110166400
Vocal cord paralysis 24.41 13.69 13 28565 2993 110557728
Spinal cord haematoma 24.28 13.69 7 28571 307 110560414
Peroneal nerve palsy 24.24 13.69 18 28560 7396 110553325
Device power source issue 23.86 13.69 10 28568 1347 110559374
Decreased appetite 23.80 13.69 55 28523 475791 110084930
Urinary tract infection 23.37 13.69 30 28548 326252 110234469
Brief psychotic disorder with marked stressors 23.34 13.69 7 28571 353 110560368
Seroma 23.27 13.69 13 28565 3288 110557433
Interstitial lung disease 23.23 13.69 4 28574 139330 110421391
Synovitis 23.15 13.69 22 28556 274070 110286651
Toxicity to various agents 23.07 13.69 207 28371 480348 110080373
Product closure issue 23.03 13.69 4 28574 14 110560707
Device kink 22.90 13.69 11 28567 2038 110558683
Withdrawal syndrome 22.86 13.69 34 28544 31346 110529375
Maternal use of illicit drugs 22.61 13.69 4 28574 16 110560705
Catheter site mass 22.59 13.69 5 28573 73 110560648
Cerebrospinal fluid leakage 22.41 13.69 11 28567 2137 110558584
Brugada syndrome 22.35 13.69 10 28568 1578 110559143
Unmasking of previously unidentified disease 22.16 13.69 12 28566 2856 110557865
Gastrointestinal disorder 22.15 13.69 18 28560 241934 110318787
Sciatic nerve palsy 22.10 13.69 5 28573 81 110560640
Product measured potency issue 21.99 13.69 6 28572 215 110560506
Cardiac failure congestive 21.81 13.69 6 28572 150994 110409727
Hypoglossal nerve disorder 21.78 13.69 3 28575 0 110560721
Femoral nerve palsy 21.77 13.69 5 28573 87 110560634
Medical device site swelling 21.66 13.69 5 28573 89 110560632
Quadriparesis 21.42 13.69 14 28564 4693 110556028
Abdominal pain upper 21.20 13.69 36 28542 349075 110211646
Nervous system disorder 21.17 13.69 33 28545 31688 110529033
Incision site pain 21.16 13.69 12 28566 3123 110557598
Lower respiratory tract infection 21.13 13.69 19 28559 243087 110317634
Drug intolerance 21.12 13.69 46 28532 406466 110154255
Premature baby 21.03 13.69 14 28564 4841 110555880
Hyperhidrosis 21.01 13.69 100 28478 187198 110373523
Bradyarrhythmia 20.82 13.69 14 28564 4920 110555801
Platelet dysfunction 20.82 13.69 7 28571 512 110560209
Wound 20.77 13.69 18 28560 234419 110326302
Fall 20.70 13.69 83 28495 603399 109957322
Symmetrical drug-related intertriginous and flexural exanthema 20.65 13.69 10 28568 1887 110558834
Quadriplegia 20.58 13.69 13 28565 4114 110556607
Pericarditis 20.43 13.69 16 28562 219098 110341623
Granuloma 20.34 13.69 18 28560 9472 110551249
Ventricular extrasystoles 20.15 13.69 27 28551 22614 110538107
Toxic anterior segment syndrome 20.08 13.69 12 28566 3442 110557279
Deafness bilateral 20.02 13.69 11 28567 2693 110558028
Extradural abscess 19.99 13.69 10 28568 2024 110558697
Pneumorrhachis 19.71 13.69 3 28575 3 110560718
Product quality issue 19.70 13.69 54 28524 77245 110483476
Implant site infection 19.67 13.69 10 28568 2093 110558628
Leukopenia 19.54 13.69 7 28571 148784 110411937
Electrocardiogram ST segment depression 19.54 13.69 14 28564 5447 110555274
Ventricular arrhythmia 19.39 13.69 18 28560 10069 110550652
Spherocytic anaemia 19.24 13.69 3 28575 4 110560717
Hiccups 19.21 13.69 20 28558 12849 110547872
Mydriasis 19.07 13.69 26 28552 22131 110538590
Maternal drugs affecting foetus 19.05 13.69 9 28569 1608 110559113
Muscle rigidity 18.90 13.69 27 28551 24004 110536717
Axillary nerve injury 18.65 13.69 4 28574 50 110560671
Product packaging confusion 18.64 13.69 6 28572 383 110560338
Corneal oedema 18.38 13.69 11 28567 3162 110557559
Tachyarrhythmia 18.37 13.69 16 28562 8245 110552476
Weight increased 18.28 13.69 52 28526 419592 110141129
Device alarm issue 18.25 13.69 10 28568 2436 110558285
Neurological procedural complication 18.17 13.69 3 28575 7 110560714
Medical device site discharge 18.03 13.69 4 28574 59 110560662
Device connection issue 17.85 13.69 8 28570 1266 110559455
Dose calculation error 17.84 13.69 6 28572 439 110560282
Hypoaesthesia oral 17.84 13.69 22 28556 16980 110543741
Abdominal discomfort 17.75 13.69 48 28530 393810 110166911
Oxygen saturation decreased 17.74 13.69 84 28494 156898 110403823
Wheezing 17.72 13.69 24 28554 255206 110305515
Psoriasis 17.69 13.69 7 28571 139986 110420735
General physical health deterioration 17.59 13.69 54 28524 425241 110135480
Alopecia 17.56 13.69 43 28535 364710 110196011
Intentional product use issue 17.53 13.69 23 28555 247883 110312838
Femoral nerve injury 17.45 13.69 4 28574 69 110560652
Fanconi syndrome 17.33 13.69 11 28567 3508 110557213
Injection site joint infection 17.13 13.69 4 28574 75 110560646
Radiculopathy 17.12 13.69 23 28555 19313 110541408
Myelopathy 17.04 13.69 13 28565 5563 110555158
Sepsis 17.04 13.69 37 28541 327309 110233412
Rhinorrhoea 17.00 13.69 3 28575 102663 110458058
Implant site swelling 17.00 13.69 6 28572 508 110560213
Paraesthesia 16.97 13.69 126 28452 276395 110284326
Spinal cord ischaemia 16.93 13.69 5 28573 239 110560482
Asthma 16.92 13.69 24 28554 250267 110310454
Hyperkalaemia 16.82 13.69 7 28571 135789 110424932
Neurogenic shock 16.81 13.69 7 28571 927 110559794
Oropharyngeal pain 16.71 13.69 7 28571 135269 110425452
Hospitalisation 16.62 13.69 8 28570 142485 110418236
Implant site scar 16.49 13.69 5 28573 262 110560459
Drug abuse 16.48 13.69 13 28565 177398 110383323
Spinal cord disorder 16.44 13.69 9 28569 2189 110558532
Implant site erythema 16.23 13.69 6 28572 580 110560141
Sphincter of Oddi dysfunction 16.21 13.69 6 28572 582 110560139
Urinary retention postoperative 16.20 13.69 5 28573 278 110560443
Intraocular pressure fluctuation 16.19 13.69 4 28574 96 110560625
Dural arteriovenous fistula 16.19 13.69 4 28574 96 110560625
Vasospasm 16.13 13.69 8 28570 1588 110559133
Dry skin 16.07 13.69 4 28574 107649 110453072
Iatrogenic injury 16.01 13.69 8 28570 1615 110559106
Nasal congestion 16.00 13.69 3 28575 98279 110462442
Cardiac output increased 15.98 13.69 6 28572 605 110560116
Stroke volume increased 15.81 13.69 3 28575 19 110560702
Administration site swelling 15.80 13.69 6 28572 625 110560096
Contraindicated product administered 15.62 13.69 25 28553 248242 110312479
Spinal epidural haematoma 15.55 13.69 8 28570 1717 110559004
Device computer issue 15.47 13.69 4 28574 116 110560605
Forceps delivery 15.41 13.69 4 28574 118 110560603
Myalgia 15.35 13.69 21 28557 222360 110338361
Procedural hypotension 15.34 13.69 9 28569 2496 110558225
Tinnitus 15.13 13.69 42 28536 60498 110500223
Brain injury 15.05 13.69 18 28560 13458 110547263
Renal failure 15.04 13.69 22 28556 226552 110334169
Tethered cord syndrome 14.98 13.69 3 28575 26 110560695
Medical device site infection 14.96 13.69 6 28572 723 110559998
Colitis 14.90 13.69 4 28574 102319 110458402
Extra dose administered 14.85 13.69 17 28561 12142 110548579
Heart rate increased 14.85 13.69 75 28503 143759 110416962
Nerve injury 14.84 13.69 16 28562 10697 110550024
Cardiac failure 14.77 13.69 16 28562 187610 110373111
Serotonin syndrome 14.75 13.69 41 28537 59112 110501609
Platelet count decreased 14.69 13.69 23 28555 230420 110330301
Staphylococcal abscess 14.65 13.69 7 28571 1282 110559439
Gastrooesophageal reflux disease 14.55 13.69 15 28563 179961 110380760
Pulmonary oedema 14.54 13.69 58 28520 100601 110460120
Anorectal disorder 14.53 13.69 9 28569 2750 110557971
Hyponatraemic encephalopathy 14.52 13.69 5 28573 393 110560328
Herpes zoster 14.40 13.69 5 28573 108374 110452347
Brain stem syndrome 14.40 13.69 7 28571 1332 110559389
Hypoglycaemia 14.36 13.69 6 28572 116098 110444623
Hypotonia 14.35 13.69 19 28559 15726 110544995
Subdural haematoma 14.18 13.69 30 28548 36424 110524297
Duodenal ulcer perforation 14.15 13.69 15 28563 177685 110383036
Meningitis aseptic 14.13 13.69 15 28563 9855 110550866
Device issue 14.11 13.69 29 28549 34506 110526215
Pre-eclampsia 13.92 13.69 14 28564 8636 110552085
Incision site rash 13.88 13.69 3 28575 39 110560682
Medication error 13.87 13.69 59 28519 105307 110455414
Neutrophil count decreased 13.79 13.69 7 28571 120934 110439787
Ocular retrobulbar haemorrhage 13.76 13.69 4 28574 181 110560540

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01BB01 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB51 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB59 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:36333 local anaesthetic
CHEBI has role CHEBI:37733 EC 3.1.1.8 (cholinesterase) inhibitor
CHEBI has role CHEBI:37887 adrenergic antagonist
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:55324 gastrointestinal drug
CHEBI has role CHEBI:59941 amphiphile
CHEBI has role CHEBI:60186 EC 3.6.3.8 (<em>Ca</em><small><sup>2+</small></sup>-transporting ATPase) inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:73336 vulnerary
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:88188 drug allergen
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175682 Amide Local Anesthetic
FDA PE N0000175976 Local Anesthesia
CHEBI has role CHEBI:38867 anaesthetic

Related Drugs by ATC class:

N01BB Amides 10 drugs
articainebutanilicainecinchocaineetidocainelevobupivacainelidocainemeloxicammepivacaineprilocaineropivacaine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anesthesia for cesarean section indication 4847005
Local anesthetic intrathecal block indication 231249005
Skin irritation indication 367466007
Local anesthesia indication 386761002
Itching of skin indication 418363000
Minor Skin Wound Pain indication
Major Nerve Block for Surgery indication
Regional Anesthesia for Surgery indication
Regional Anesthesia for Labor Pain indication
Regional Anesthesia for Ophthalmologic Surgery indication
Regional Anesthesia for Postoperative Pain indication
Local Anesthesia for Ophthalmologic Procedure indication
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Sinus tachycardia contraindication 11092001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Constipation contraindication 14760008 DOID:2089
Chronic disease of respiratory system contraindication 17097001
Mood swings contraindication 18963009
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Alcohol intoxication contraindication 25702006
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Decreased cardiac function contraindication 43650005
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Atrial fibrillation contraindication 49436004 DOID:0060224
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Sinus bradycardia contraindication 49710005
Bleeding hemorrhoids contraindication 51551000
Paralytic ileus contraindication 55525008 DOID:8442
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Cerebral arteriosclerosis contraindication 65312002
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Cor pulmonale contraindication 83291003 DOID:8515
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of mucous membrane contraindication 95351003
Disorder of biliary tract contraindication 105997008 DOID:9741
Acute abdominal pain contraindication 116290004
Procedure on urinary system contraindication 118677009
Open wound contraindication 125643001
Neoplasm of brain contraindication 126952004 DOID:1319
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Drug-induced psychosis contraindication 191483003 DOID:1742
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Partial atrioventricular block contraindication 195039008
Disease of liver contraindication 235856003 DOID:409
Morbid obesity contraindication 238136002 DOID:11981
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Exacerbation of asthma contraindication 281239006
Lesion of brain contraindication 301766008
Deficiency of cholinesterase contraindication 360607009
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Central nervous system depression contraindication 418072004
Denuded skin contraindication 418242004
Dysfunction of sphincter of Oddi contraindication 430887001
Acute exacerbation of asthma contraindication 708038006
Reduced Hepatic Blood Flow contraindication
Lidocaine Toxicity contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Regional postoperative analgesia after onychocomy Indication
Dogs Local postoperative analgesia for cranial cruciate ligament surgery Indication

🐶 Veterinary products

ProductApplicantIngredients
Nocita Elanco US Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 7.92 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG XARACOLL INNOCOLL PHARMS N209511 Aug. 28, 2020 DISCN IMPLANT IMPLANTATION RE47826 May 20, 2029 A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11413350 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11844837 April 21, 2036 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11844837 April 21, 2036 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11844837 April 21, 2036 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11844837 April 21, 2036 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
660MG/5ML (132MG/ML) POSIMIR INNOCOLL N204803 Feb. 1, 2021 DISCN SOLUTION INFILTRATION 11771624 Jan. 12, 2041 TO PRODUCE POST-SURGICAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11033495 Jan. 22, 2041 METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11179336 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11278494 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11304904 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11311486 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11357727 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11426348 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11452691 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11819574 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11819575 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11925706 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12144890 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE POSTSURGICAL LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE POSTSURGICAL REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12151024 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12296047 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA A NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11033495 Jan. 22, 2041 METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11179336 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11278494 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11304904 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11311486 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11357727 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11426348 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11452691 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11819574 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11819575 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11925706 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12144890 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE POSTSURGICAL LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE POSTSURGICAL REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12151024 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12296047 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA A NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11931459 March 17, 2042 A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 12 YEARS OLD UNDERGOING CARDIAC SURGERY
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11931459 March 17, 2042 A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 17 YEARS OLD UNDERGOING SPINE SURGERY
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11931459 March 17, 2042 A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 12 YEARS OLD UNDERGOING CARDIAC SURGERY
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11931459 March 17, 2042 A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 17 YEARS OLD UNDERGOING SPINE SURGERY
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11918565 Feb. 2, 2043 A METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE REGIONAL ANALGESIA VIA SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA IN ADULTS
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA VIA AN ADDUCTOR CANAL BLOCK IN ADULTS
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF INCREASING THE AMOUNT OF TIME BEFORE POSTSURGICAL OPIOID MEDICATION IS ADMINISTERED TO A PATIENT BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF REDUCING POSTSURGICAL OPIOID CONSUMPTION BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11918565 Feb. 2, 2043 A METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE REGIONAL ANALGESIA VIA SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA IN ADULTS
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA VIA AN ADDUCTOR CANAL BLOCK IN ADULTS
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF INCREASING THE AMOUNT OF TIME BEFORE POSTSURGICAL OPIOID MEDICATION IS ADMINISTERED TO A PATIENT BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12226610 Feb. 2, 2043 METHOD OF REDUCING POSTSURGICAL OPIOID CONSUMPTION BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12251468 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12318483 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12370142 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12251468 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12318483 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 12370142 July 2, 2044 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION Nov. 9, 2026 INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION Nov. 9, 2026 INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR Jan. 23, 2027 REVISIONS TO THE LABELING TO EXPAND THE USE IN CERTAIN SOFT TISSUE AND CERTAIN ORTHOPEDIC SURGICAL PROCEDURES AS WELL AS REVISING THE LIMITATIONS OF USE
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR Jan. 23, 2027 REVISIONS TO THE LABELING TO EXPAND THE USE IN CERTAIN SOFT TISSUE AND CERTAIN ORTHOPEDIC SURGICAL PROCEDURES AS WELL AS REVISING THE LIMITATIONS OF USE
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR Jan. 23, 2027 REVISIONS TO THE LABELING TO EXPAND THE USE IN CERTAIN SOFT TISSUE AND CERTAIN ORTHOPEDIC SURGICAL PROCEDURES AS WELL AS REVISING THE LIMITATIONS OF USE
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR Jan. 23, 2027 REVISIONS TO THE LABELING TO EXPAND THE USE IN CERTAIN SOFT TISSUE AND CERTAIN ORTHOPEDIC SURGICAL PROCEDURES AS WELL AS REVISING THE LIMITATIONS OF USE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 4 subunit alpha Ion channel BLOCKER IC50 6 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.66 CHEMBL
Sodium channel protein type 1 subunit alpha Ion channel IC50 5.29 WOMBAT-PK
Prostaglandin E2 receptor EP1 subtype GPCR IC50 5.51 WOMBAT-PK
Cytochrome P450 2D6 Enzyme IC50 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel IC50 4.23 WOMBAT-PK
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 4.50 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 5 Ion channel BLOCKER Kd 5.40 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 4.39 CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.66 IUPHAR
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 4.50 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 4.39 CHEMBL
Potassium channel subfamily K member 9 Ion channel IC50 4 CHEMBL

External reference:

IDSource
4019643 VUID
N0000147736 NUI
D07552 KEGG_DRUG
18010-40-7 SECONDARY_CAS_RN
73360-54-0 SECONDARY_CAS_RN
1375412 RXNORM
C0006400 UMLSCUI
CHEBI:3215 CHEBI
CHEMBL1098 ChEMBL_ID
CHEMBL1200396 ChEMBL_ID
DB00297 DRUGBANK_ID
D002045 MESH_DESCRIPTOR_UI
2474 PUBCHEM_CID
2397 IUPHAR_LIGAND_ID
C472824 MESH_SUPPLEMENTAL_RECORD_UI
2279 INN_ID
Y8335394RO UNII
3621 MMSL
39700 MMSL
4305 MMSL
d00180 MMSL
1268954003 SNOMEDCT_US
24022008 SNOMEDCT_US
27196008 SNOMEDCT_US
387150008 SNOMEDCT_US
4018244 VANDF
4019643 VANDF
001341 NDDF
005054 NDDF
Y8335394RO INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9328 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 25 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9329 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 25 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9330 INJECTION, SOLUTION 2.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9331 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9332 INJECTION, SOLUTION 7.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9333 INJECTION, SOLUTION 2.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9334 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9335 INJECTION, SOLUTION 7.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride with Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-9379 INJECTION 7.50 mg SUBARACHNOID ANDA 24 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0557 INJECTION, SOLUTION 5 mg SUBMUCOSAL ANDA 19 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0557 INJECTION, SOLUTION 5 mg SUBMUCOSAL ANDA 19 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 5 mg SUBMUCOSAL ANDA 19 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9768 INJECTION, SOLUTION 5 mg EPIDURAL NDA 16 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9770 INJECTION, SOLUTION 2.50 mg EPIDURAL NDA 17 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9779 INJECTION, SOLUTION 5 mg EPIDURAL NDA 16 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9826 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 17 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9826 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 17 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9827 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 17 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9827 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 17 sections
Bupivacaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9828 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 12 sections
Bupivacaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9828 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 12 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9907 INJECTION, SOLUTION 5 mg EPIDURAL NDA 17 sections
MARCAINE WITH EPINEPHRINE HUMAN PRESCRIPTION DRUG LABEL 2 0404-9908 INJECTION, SOLUTION 2.50 mg INFILTRATION NDA 17 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9945 INJECTION, SOLUTION 2.50 mg INFILTRATION NDA 17 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9945 INJECTION, SOLUTION 2.50 mg INFILTRATION NDA 17 sections
Sensorcaine MPF HUMAN PRESCRIPTION DRUG LABEL 1 0404-9946 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 16 sections
Sensorcaine MPF HUMAN PRESCRIPTION DRUG LABEL 1 0404-9946 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 16 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9947 INJECTION, SOLUTION 5 mg PERINEURAL NDA 11 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9947 INJECTION, SOLUTION 5 mg PERINEURAL NDA 11 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0409-0525 INJECTION, SOLUTION 250 mg PERINEURAL NDA 28 sections